Clinical trial NCT04208399: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379
Official title: A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-56136379
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatic Impairment
Lead sponsor: Janssen Sciences Ireland UC
Sponsor class: INDUSTRY
First posted: 2019-12-23
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of JNJ-56136379 in participants with liver cirrhosis and impaired hepatic function when compared with healthy participants with normal hepatic function and no liver cirrhosis.


Eligibility criteria: Inclusion criteria:

* For all participants: Body mass index (BMI) between 18.0 and 38 kilogram per meter square (kg/m2), extremes included; Woman of childbearing potential must not be pregnant; Highly effective contraceptive measures in place for female participants of childbearing potential or male participants with female partners of childbearing potential; Non-smoker or light smoker as defined per protocol.
* For Healthy Participants with Normal Hepatic Function and No Liver Cirrhosis: Demographically comparable to the study groups with hepatic impairment with respect to sex, age (+/-10 years), and body weight (+/-10 kilogram \[kg\]); Participants must be in good health clinically and biologically as defined per protocol.
* For Participants with Liver Cirrhosis and Moderate or Mild or Severe Hepatic Impairment: Must have a total Child-Pugh score of 5 or 6, inclusive (mild); or 7 to 9, inclusive (moderate); or 10 to 15, inclusive (severe) as determined by the investigator; Must have liver cirrhosis with fibro scan readout greater than (\>) 12.5 Kilopascal (kPa) as cut-off at screening
* Participants with controlled hypertension, with problems directly associated with the primary diagnosis of hepatic impairment and with concurrent stable medical conditions if the condition(s) will not introduce an additional risk factor and will not interfere with the study objectives.
* Concomitant medications to treat underlying disease states or medical conditions related to hepatic impairment are allowed.

Exclusion Criteria:

* History of / or current clinically significant medical illness that could interfere with the interpretation of the study results.
* Known allergies, hypersensitivity, or intolerance to JNJ-6379 or its excipients.
* History of drug or alcohol abuse within 1 year before screening or positive test results at screening and Day -1.
* Blood or blood products donated or substantial loss of blood (more than 500 milliliters \[mL\]) within 3 months before the study starts
* Experimental drug received (including investigational vaccines) or experimental medical device used within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before the first dose of the study intervention is scheduled.
* Evidence of infection with human immunodeficiency virus (HIV)-1 and HIV-2, hepatitis A, B or C (except if sustained virologic response to hepatitis C virus \[HCV\] treatment).
* Inability to fast for 10 hours.
* Signs of hepatocellular carcinoma or history of biliary obstruction within the past 2 years.
* Lack of good or reasonable venous access.

Primary outcomes:
measure: Plasma Concentration of JNJ-56136379
timeFrame: Up to Day 21
Secondary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Munchen
country: Germany
facility: APEX GmbH
Study officials:
affiliation: Janssen Sciences Ireland UC
name: Janssen Sciences Ireland UC Clinical Trials
role: STUDY_DIRECTOR
References: